AngioDynamics (NASDAQ: ANGO) Fiscal Q1 2027 Earnings Report and Financial Performance

Font: Financial Modeling Prep  • Oct 08, 2026

• Reported a smaller than expected loss of $0.04 per share for its fiscal 2027 first-quarter results.
• Revenue reached $80.90 million, slightly exceeding initial estimates.
• Announced a significant leadership change, with Eric Honroth appointed to succeed Jim Clemmer as CEO.

AngioDynamics (NASDAQ: ANGO) is a medical technology company. It reported fiscal 2027 first-quarter results before the market opened on October 8, 2026. Its loss was $0.04 per share, smaller than the roughly $0.11 loss estimated in the initial figures. A smaller loss means the company lost less money per share than expected.

Revenue was $80.90 million, slightly above the initial estimate of $80.50 million. Estimates can differ by source: as highlighted by Zacks, revenue of $80.92 million was 0.03% below the consensus estimate it used. Zacks also reported an adjusted loss of $0.04 per share, compared with its expected loss of $0.10.

As highlighted by MarketBeat, revenue grew 6.9% from a year earlier, and AngioDynamics maintained its full-year outlook. Med Tech revenue rose 13.2% to $39.90 million. The segment accounted for 49% of total revenue, up from 47% a year earlier, making it a larger part of the business.

AngioDynamics also announced a leadership change. Eric Honroth will succeed Jim Clemmer as president and CEO on November 2. Honroth previously led Getinge’s $1.20 billion North American business. Clemmer said he would help with the transition.